北京康弘生物医药

Beijing Kanghong Biological Medicine is a specialized biotechnology subsidiary of Chengdu Kanghong Pharmaceutical Group, focused on the development and commercialization of innovative biologics. The company's flagship product, Conbercept (Langmu), is a recombinant fusion protein that has become a leading treatment for neovascular age-related macular degeneration and other retinal diseases in China. Conbercept was notably the first innovative biological drug in China to receive an international non-proprietary name from the World Health Organization. Beyond its commercial success in ophthalmology, the company is advancing a pipeline that includes gene therapies and treatments for oncology. Beijing Kanghong maintains sophisticated R&D and GMP-certified manufacturing facilities in Beijing to support its mission of providing high-quality biological therapeutics. The company continues to expand its global footprint through clinical trials and strategic research initiatives.